Circulating insulin and insulin growth factor-1 are independent determinants of left ventricular mass and geometry in essential hypertension

Circulation

Volumn 100, Issue 17, 1999, Pages 1802-1807

  Verdecchia, Paolo ^a,b   Reboldi, Gianpaolo ^c   Schillaci, Giuseppe ^c   Borgioni, Claudia ^a   Ciucci, Antonella ^a   Telera, Maria Pia ^a   Santeusanio, Fausto ^c   Porcellati, Carlo ^a   Brunetti, Paolo ^c  

^a Osp Gen Regionale Raffaello S   (Italy)

^b Dipto di Discipline Cardiovascolari   (Italy)

^c NONE

Author keywords

Echocardiography; Growth substances; Hypertension; Hypertrophy; Insulin

Indexed keywords

INSULIN; SOMATOMEDIN C;

ADULT; AGE; ARTICLE; BLOOD PRESSURE MONITORING; BODY MASS; CARDIOVASCULAR RISK; ECHOCARDIOGRAPHY; ESSENTIAL HYPERTENSION; FEMALE; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HEART LEFT VENTRICLE WALL; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL; SEX; STATISTICAL ANALYSIS;

EID: 0032756288     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.100.17.1802     Document Type: Article

References (41)

1. Koren MJ, Devereux RB, Casale PN, Savage DD, Laragh JH. Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Ann Intern Med. 1991;114:345-352.
2. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham heart study. N Engl J Med. 1990;322:1561-1566.
3. Verdecchia P, Porcellati C, Schillaci G, Borgioni C, Ciucci A, Battistelli M, Guerrieri M, Gatteschi C, Zampi I, Santucci A, Santucci C, Reboldi G. Ambulatory blood pressure: an independent predictor of prognosis in essential hypertension. Hypertension. 1994;24:793-801.
4. Muiesan ML, Salvetti M, Rizzoni D, Castellano M, Donato F, Agabiti-Rosei E. Association of change in left ventricular mass with prognosis during long-term antihypertensive treatment. J Hypertens. 1995;13:1091-1095.
5. Verdecchia P, Schillaci G, Borgioni C, Ciucci A, Gattobigio R, Zampi I, Reboldi G, Porcellati C. Prognostic significance of serial changes in left ventricular mass in essential hypertension. Circulation. 1998;97:48-54.
6. Devereux RB, Roman MJ. Hypertensive cardiac hypertrophy: pathophysiologic and clinical characteristics. In: Laragh JH, Brenner BM, eds. Hypertension: Pathophysiology, Diagnosis and Management. 2nd ed. New York, NY: Raven Press, Ltd; 1995:409-424.
7. Denker PS, Pollock VE. Fasting serum insulin levels in essential hypertension: a meta-analysis. Arch Intern Med. 1992;152:1649-1651.
8. Lind L, Andersson P-E, Andrén B, Hanni A, Lithell HO. Left ventricular hypertrophy in hypertension is associated with the insulin resistance metabolic syndrome. J Hypertens. 1995;13:433-438.
9. Hill DJ, Millner DG. Insulin as a growth factor. Pediatr Res. 1985;19: 879-886.
10. Ito H, Hiroe M, Hirata Y, Tsujino M, Shichiri M. Insulin-like growth factor-I induces cardiac hypertrophy with enhanced expression of muscle-specific genes in cultured rat cardiomyocytes. Circulation. 1993;87: 1715-1721.
11. Strauss DS. Growth-stimulatory actions of insulin in vitro and in vivo. Endocr Rev. 1984;5:356-367.
12. Diez J, Laviades C, Martinez E, Gil MJ, Monreal I, Fernandez J, Prieto J. Insulin-like growth factor binding proteins in arterial hypertension: relationship to left ventricular hypertrophy. J Hypertens. 1995;13: 349-355.
13. Verdecchia P, Schillaci G, Boldrini F, Guerrieri M, Zampi I, Porcellati C. Quantitative assessment of day-to-day spontaneous variability in non-invasive ambulatory blood pressure measurements in essential hypertension. J Hypertens. 1991;9(suppl 6):S322-S323.
14. Fagard R, Brguljan J, Thijs L, Staessen J. Prediction of the actual awake and asleep blood pressures by various methods of 24h pressure analysis. J Hypertens. 1996;14:557-563.
15. Sahn DJ, DeMaria A, Kisslo J, Weyman A, the Committee on M-Mode Standardization of the American Society of Echocardiography. Recommendations regarding quantitation in M-mode echocardiography: results of a survey of echocardiographic measurements. Circulation. 1978;58:1072-1083.
16. Devereux RB, Alonso DR, Lutas EM, Gottlieb GJ, Campo E, Sachs I, Reichek N. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol. 1986;57:450-458.
17. de Simone G, Daniels SR, Devereux RB, Meyer RA. Roman MJ, de Divitiis O, Alderman MH. Left ventricular mass and body size in normotensive children and adults: assessment of allometric relations and of the impact of overweight. J Am Coll Cardiol. 1992;20:1251-1260.
18. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentration in man. Diabetologia. 1985;28:412-419.
19. Bonora E, Kiechl S, Willeit J, Oberhollenzer F, Egger G, Targher G, Alberiche M, Bonadonna RC, Muggeo M. Prevalence of insulin resistance in metabolic disorders: the Bruneck Study. Diabetes. 1998;47:1643-1649.
20. Marcus R, Krause L, Weder AB, Dominguez-Majia A, Schork NJ, Julius S. Sex-specific determinants of increased left ventricular mass in the Tecumseh blood pressure study. Circulation. 1994;90:928-936.
21. Paolisso G, Galderisi M, Tagliamonte MR, de Divitis M, Galzerano D, Petrocelli A, Gualdiero P, de Divitis O, Varricchio M. Myocardial wall thickness and left ventricular geometry in hypertensives: relationship with insulin. Am J Hypertens. 1997;10:1250-1256.
22. Phillips RA, Krakoff LR, Dunaif A, Finegood DT, Gorlin R, Shimabukuro S. Relation among left ventricular mass, insulin resistance, and blood pressure in nonobese subjects. J Clin Endocrinol Metab. 1998;83: 4284-4288.
23. Diez J, Laviades C. Insulin-like growth factor-1 and cardiac mass in essential hypertension: comparative effects of captopril, lisinopril and quinapril. J Hypertens. 1994;12(suppl 4):S31-S36.
24. Andronico G, Mangano M-T, Nardi E, Mulè G, Piazza G, Cerasola G. Insulin-like growth factor 1 and sodium-lithium countertransport in essential hypertension and in hypertensive left ventricular hypertrophy. J Hypertens. 1993;11:1097-1101.
25. Verdecchia P, Schillaci G, Borgioni C, Ciucci A, Battistelli M, Bartoccini C, Santucci A, Santucci C, Reboldi G, Porcellati C. Adverse prognostic significance of concentric remodeling of the left ventricle in hypertensive subjects with normal left ventricular mass. J Am Coll Cardiol. 1995;25: 871-878.
26. Krumholz HM, Larson M, Levy D. Prognosis of left ventricular geometric patterns in the Framingham Heart Study. J Am Coll Cardiol. 1995;25:879-884.
27. Verdecchia P, Schillaci G, Borgioni C, Ciucci A, Gattobigio R, Zampi I, Santucci A, Santucci C, Reboldi G, Porcellati C. Prognostic value of left ventricular mass and geometry in systemic hypertension with left ventricular hypertrophy. Am J Cardiol. 1996;78:197-202.
28. Ghali JK, Liao Y, Cooper RS. Influence of left ventricular geometric patterns on prognosis in patients with or without coronary artery disease. J Am Coll Cardiol. 1998;31:1635-1640.
29. Reaven GM, Lithell H, Landsberg L. Hypertension and associated metabolic abnormalities: the role of insulin resistance and sympathoadrenal system. N Engl J Med. 1996;334:374-381.
30. Anderson EA, Balon TW, Hoffman RP, Sinkey CA, Mark AL. Insulin increases sympathetic activity but not blood pressure in borderline hypertensive humans. Hypertension. 1992;19:621-627.
31. DeFronzo RA, Cooke CR, Andres R, Faloona GR, Davis PJ. The effect of insulin on renal handling of sodium, potassium, calcium, and phosphate in man. J Clin Invest. 1975;55:845-855.
32. Robertson AL, Khairallah PA. Angiotensin II: rapid localization in nuclei of smooth and cardiac muscle. Science. 1971;172:1138-1139.
33. Devereux RB, Savage DD, Drayer JIM, Laragh JH. Left ventricular hypertrophy and function in high, normal, and low-renin forms of essential hypertension. Hypertension. 1982;4:524-531.
34. Muscholl MW, Schunkert H, Muders F, Elsner D, Kuch B, Hense HW, Riegger GA. Neurohormonal activity and left ventricular geometry in patients with essential arterial hypertension. Am Heart J. 1998;135:58-66.
35. Schunkert H, Hense H, Hollmer SR, Stender M, Perz S, Keil U, Lorell BH, Riegger GAJ. Association between a deletion polymorphism of the angiotensin-converting-enzyme gene and left ventricular hypertrophy. N Engl J Med. 1994;330:1634-1638.
36. Lindpaintner K, Lee M, Larson M, Rao VS, Pfeffer M, Ordovas JM, Schaefer EJ, Wilson AF, Wilson PWF, Vasan RS, Myers RH, Levy D. Absence of association or genetic linkage between the angiotensin-converting-enzyme gene and left ventricular mass. N Engl J Med. 1996; 334:1023-1028.
37. Cohick WS, Clemmons DR. The insulin-like growth factor. Annu Rev Physiol. 1993;55:131-153.
38. Donath MY, Zapf J, Eppenberger-Eberhardt M, Froesch ER, Eppenberger HM. Insulin-like growth factor I stimulates myofibril development and decreases smooth muscle cell α-actin on adult cardiomyocytes. Proc Natl Acad Sci U S A. 1994;91:1686-1690.
39. Jones JL, Clemmons DR. Insulin-like growth factors and their binding proteins: biological actions. Endocr Rev. 1995;16:3-34.
40. Laviades C, Gil MJ, Monreal I, Gonzalez A, Diez J. Tissue availability of insulin-like growth factor I is inversely related to insulin resistance in essential hypertension: effects of angiotensin converting enzyme inhibition. J Hypertens. 1998;16:863-870.
41. Ruige JTB, Assendelft WJJ, Dekker JM, Kostense PJ, Heine RJ, Bouter LM. Insulin and risk of cardiovascular disease: a meta-analysis. Circulation. 1998;97:996-1001.